Allogene Therapeutics
Thomas F. Gajewski, MD, PhD is a Professor of medicine and pathology at the University of Chicago as well as a practicing physician specializing in hematology and oncology. Throughout his career, Dr. Gajewski has focused on understanding fundamental aspects of anti-tumor immunity and bringing these concepts forward from the laboratory into clinical trials. An author of more than 250 manuscripts, 20 book chapters, and speaker at over 200 scientific conferences, Dr. Gajewski is the founding editor of the Journal for Immunotherapy of Cancer. He has served as past president of the Society for Immunotherapy of Cancer, past chair of the Cancer Immunopathology and Immunotherapy grant review study section at the National Institutes of Health, served on the program committees for the American Society of Clinical Oncology and the American Association for Cancer Research, and is a grant reviewer for the Melanoma Research Alliance and Cancer Research Institute. He received a BS, PhD in Immunology, and MD degrees from the University of Chicago.
This person is not in the org chart
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.